KMB — Claude Opus 4.8

I'll research KMB before writing the preview. Let me gather recent earnings materials, guidance, and news.Let me read the most recent quarter (Q1 2026) release and call, and check for recent news.Let me get the prior-year Q2 2025 release (the quarter being lapped) and recent stock price and news.Let me check recent news on the Kenvue deal and Q2 expectations.Let me get the latest on the Kenvue deal status via web search for context.I have what I need. Let me quickly compute a few price stats for accuracy.# Kimberly-Clark (KMB) — Q2 2026 Earnings Preview

Report date: Tuesday, August 4, 2026 | Release ~6:30 a.m. ET, analyst Q&A 8:00 a.m. ET

The one thing that matters: this is a "sum-of-the-parts" quarter, not just a P&L print

KMB is no longer a straightforward staples story. The stock now trades primarily as a merger-arbitrage / deal-completion vehicle layered on top of a solid organic-growth engine. Going into the print, investors need to weigh three separate things:

The pending ~$48.7B acquisition of Kenvue (KVUE) — the dominant driver of the equity.
The IFP joint-venture with Suzano — expected to close mid-2026, funding part of the Kenvue cash consideration.
The underlying base business, which is executing well but faces a fresh input-cost/oil headwind that management deliberately left outside guidance last quarter.

Because both transactions are outstanding, the quarterly EPS number matters less than usual; the guidance commentary, cost-mitigation plan, and deal timeline updates are what will move the stock.

Note: Unlike KMB, Kenvue is not hosting a call this cycle (press release only) due to the pending transaction — so KMB's Q&A is the main live event.

Setup / what the Street is anchored to

Prior-year comp (Q2 2025 — the hardest of the year to lap): - Net sales (continuing ops): $4.16B, organic +3.9%, driven by +5.0% volume — the strongest volume quarter in five years - Adjusted operating profit: $713M - Adjusted EPS from continuing ops: $1.63; Adjusted EPS attributable to K-C: $1.92

Most recent quarter (Q1 2026): - Organic sales +2.5% (volume/mix +3.0%, price -0.5%) - Adjusted operating profit $732M (+3.7%); adjusted operating margin +~20 bps - Adjusted EPS continuing ops $1.60 (-1.2%) — pressured by a higher adjusted tax rate (26.2% vs 20.7%) - Adjusted EPS attributable to K-C $1.97 (+2.1%) - Segments: North America organic +1.8% (but -0.6% reported on private-label diaper exit); International Personal Care organic +4.0%, reported +9.1% on FX tailwind

What management guided for Q2 2026 specifically (from the Q1 call)

This is the roadmap to judge the print against:

Item	Q2 2026 guide
Organic sales growth	Slightly below Q1's +2.5% — lapping ~+4% total / +5% NA volume comp
California DC fire	~$20M top-line hit (~70–80 bps drag on North America)
Bottom-line headwind	~$50M from Middle East-war-driven inflation + the LA DC fire, expected to be recovered in 2H
Margins	Gross and operating margin expected to expand as the year progresses (PL-diaper drag fully lapped after Q2)

The key nuance: management said the ~$50M Q2 hit is manageable and left it in the outlook, but explicitly kept the full-year guide unchanged while its teams work through mitigation.

The big open question: the 2H oil/input-cost overhang

On the Q1 call, CFO Nelson Urdaneta flagged that if oil averages ~$100/bbl, 2H gross incremental input costs could be $150–170M — and stressed this was NOT yet in guidance, nor were any offsetting actions. Management's framing:

~80% of the cost basket is covered via contracts/hedging.
Levers to offset: revenue growth management (RGM)/pricing, ~6% gross productivity, supplier renegotiation, price-pack architecture.
Philosophy is "pricing net of cost neutral over time" (PNOC) — they've absorbed $1.6–1.7B/yr shocks in 2022–23 and still expanded margins.

What to watch: Does KMB (a) quantify updated input-cost inflation, (b) lay out concrete mitigation, and (c) hold, trim, or reaffirm the FY guide? Bears (e.g., TD Cowen's Moskow on the last call) note that in 2025 KMB still had to cut profit guidance despite mitigating tariffs — so credibility on "we'll offset it" is a live debate. A guidance cut here would be the main negative surprise risk; conversely, a clean reaffirmation with a credible offset plan would be a relief.

Full-year 2026 framework (reaffirmed at Q1) — the bar for any revision

Organic sales: in line to ahead of category growth (~2.5% LTM)
Reported net sales: ~-50 bps from private-label diaper exit, ~+50 bps FX
Adjusted operating profit: mid-to-high single-digit growth, constant currency
Adjusted EPS from continuing ops: double-digit growth, constant currency (helped by ~40% higher equity-company income, flat net interest, ~23% adjusted tax rate, flat share count)
Adjusted EPS attributable to K-C: flat constant currency (discontinued-ops/IFP income falls as the Suzano deal closes mid-year); ~+170 bps FX tailwind
Adjusted free cash flow context: ~$2B was the 2025 target

Note the two different EPS goalposts — continuing-ops EPS (growing double digits) vs. total attributable EPS (flat, dragged by the IFP wind-down). Expect confusion in headlines; focus on continuing ops.

Deal tracker (the real stock driver)

Kenvue acquisition (announced Nov 3, 2025): - Terms: $3.50 cash + 0.14625 KMB shares per KVUE share (~$21.01/sh at announcement); ~$48.7B EV / ~$40B equity. Post-close ownership ~54% legacy KMB / ~46% legacy KVUE. - Cash funded via cash on hand, new debt, and IFP transaction proceeds. - Shareholders (both sides) approved Jan 29, 2026 (~96% of KMB shares voted; ~99% of KVUE shares voted). HSR waiting period expired Feb 4, 2026. - Now in an FTC "second request" review; management still guides to a 2H 2026 close. - Strategic thesis (per Hsu): Kenvue's issues are "executional, not structural" (mainly NA skin care, NA oral care, China); >40 integration teams running; synergy line-of-sight across COGS, SG&A, and revenue.

IFP / Suzano JV: expected to close mid-2026; proceeds part-fund the Kenvue cash. Watch for any confirmation it has closed or slipped.

What to watch: any update on FTC engagement/timing, financing terms, expected synergies quantification, or a firmer close date. Given the FTC's stated focus on consumer-essentials concentration, regulatory commentary is the highest-beta item on the call.

Business fundamentals to monitor

North America: Is innovation-led volume still driving share (diapers/Huggies trial via Snug & Dry promo; club-channel distribution normalization) without margin-destructive promotion? Watch shipment-vs-consumption timing (Q1 consumption ran ~200 bps ahead of shipments).
International Personal Care: Strong momentum — Southeast Asia (Vietnam), India, Australia, and a Korea baby-boom tailwind (category +20%, KMB ~60% share). Watch Middle East/Red Sea shipping disruption and FX (Argentina/Türkiye).
Productivity: Tracking to ~6% gross productivity and the ~$200M Powering Care overhead savings — the fuel for reinvestment and cost offset.
Tax: Adjusted rate stepped up (~26% in Q1 vs ~23% full-year target) — watch the trajectory, as it's been the main EPS swing factor.

Stock context

KMB closed $107.59 on Aug 3, 2026 — roughly +6% YTD, +9% since the Q1 print (Apr 28), and +16% off the early-April low (~$93), but ~6% below the early-July high (~$114.72).
The shares and KVUE have traded tightly correlated since the deal (KMB is now KVUE's largest price driver via the stock component), so KMB's reaction will partly reflect deal-spread sentiment, not just fundamentals.
After a strong June–July run, expectations have risen — raising the bar for a positive surprise.

Bottom line — what would move the stock

Bullish: FY guide reaffirmed with a credible 2H cost-offset plan; confirmation of on-track FTC process / 2H close; IFP close confirmed; continued NA share gains + IPC strength.

Bearish: Any trim to the FY profit/EPS outlook on oil/input costs; softer-than-guided organic growth against the tough comp (remember: guided slightly below +2.5%); FTC friction, remedy/divestiture chatter, or a pushed-out close; unexpected deal-financing cost.

Base case: A "beat-but-noisy" quarter on the headline (helped by FX and productivity) with all eyes on (1) the input-cost mitigation message and (2) Kenvue/FTC timing. Trade the guidance and deal commentary, not the EPS line.

Sources: KMB Q1 2026 and Q2 2025 earnings releases and transcripts; KMB/KVUE merger filings and press releases; historical price data through Aug 3, 2026. Figures reflect continuing operations unless noted. This is an informational preview, not investment advice.